Aktie KLY KALYTERA THERAPEUTICS INC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Kalytera Therapeutics Inc Toronto S.E.

Aktien

KLY

CA48349P1036

KLY

Schlusskurs Toronto S.E.
Andere Börsenplätze
 		% 5 Tage % 1. Jan.
- PTS -.--% Intraday Chart für Kalytera Therapeutics Inc -.--% -.--%
2021 Claritas aktualisiert vorgeschlagene Finanzierung mit Obsidian, erhält australische Steuergutschrift, beginnt Phase-1-Studie mit R-107 MT
2021 Claritas Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2021 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107
Claritas Pharmaceuticals : IIROC Trading Resumption - CLAS
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107
Claritas Pharmaceuticals : IIROC Trading Halt - CLAS
Claritas Announces Grant of Stock Options to Directors and Officers
Claritas Pharmaceuticals : Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107
Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107
Claritas Pharmaceuticals : Reports Additional Data in Animal Model of Pulmonary Arterial Hypertension Treatment, R-107
Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease
Claritas Pharmaceuticals : 1-For-20 Share Consolidation Effective July 23
Claritas Announces Effective Date for Share Consolidation
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) dropped from S&P/TSX Venture Composite Index
Claritas Pharmaceuticals : Announces Commitments from Company's Largest Shareholders to Vote for Approval of Share Consolidation
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics
Claritas Pharmaceuticals : Announces Settlement of Debt Transaction
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
Claritas Pharmaceuticals Issues Letter to Shareholders
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CSQG Aktie
  4. KLY Aktie
  5. Nachrichten Kalytera Therapeutics Inc
  6. Andere Sprachen